mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase

doi:10.1016/j.jaip.2021.09.051

. 2022 Jan;10(1):322-325.

doi: 10.1016/j.jaip.2021.09.051. Epub 2021 Oct 20.

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase

Affiliations

¹ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
² Department of Pediatrics, Baylor College of Medicine, Houston, Texas; Section of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Houston, Texas; William T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, Texas.
³ Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tenn.
⁴ Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn.
⁵ Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tenn.
⁶ Department of Pediatric Pharmacy, Pharmacology, Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tenn.
⁷ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tenn; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
⁸ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: cosby.a.stone@vumc.org.

PMID: 34678498
PMCID: PMC8526431
DOI: 10.1016/j.jaip.2021.09.051

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase

Grace Koo et al. J Allergy Clin Immunol Pract. 2022 Jan.

. 2022 Jan;10(1):322-325.

doi: 10.1016/j.jaip.2021.09.051. Epub 2021 Oct 20.

Authors

Affiliations

¹ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
² Department of Pediatrics, Baylor College of Medicine, Houston, Texas; Section of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Houston, Texas; William T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, Texas.
³ Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tenn.
⁴ Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn.
⁵ Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tenn.
⁶ Department of Pediatric Pharmacy, Pharmacology, Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tenn.
⁷ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tenn; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
⁸ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: cosby.a.stone@vumc.org.

PMID: 34678498
PMCID: PMC8526431
DOI: 10.1016/j.jaip.2021.09.051

No abstract available

PubMed Disclaimer

Cited by

Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy.
Broos N, Brigitha LJ, Schuurhof A, Röckmann-Helmbach H, Tissing WJE, Pieters R, van der Sluis IM, Stadermann MB. Broos N, et al. EJC Paediatr Oncol. 2023;1:100002. doi: 10.1016/j.ejcped.2022.100002. Epub 2022 Dec 24. EJC Paediatr Oncol. 2023. PMID: 38013843 Free PMC article.
SARS-CoV-2 and allergy - what have we learned after two and a half years?
Brockow K, Wang R, Mathes S, Bent R, Faihs V, Eberlein B, Darsow U, Biedermann T. Brockow K, et al. Allergol Select. 2023 Mar 31;7:101-112. doi: 10.5414/ALX02373E. eCollection 2023. Allergol Select. 2023. PMID: 37056446 Free PMC article. Review.
The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis.
Khalid MB, Frischmeyer-Guerrerio PA. Khalid MB, et al. J Allergy Clin Immunol Glob. 2023 Feb;2(1):1-13. doi: 10.1016/j.jacig.2022.10.003. Epub 2022 Dec 13. J Allergy Clin Immunol Glob. 2023. PMID: 36532656 Free PMC article. Review.
Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID-19 vaccines: A systematic review and meta-analysis.
Greenhawt M, Shaker M, Golden DBK, Abrams EM, Blumenthal KG, Wolfson AR, Stone CA Jr, Krantz MS, Chu DK, Dwamena BA. Greenhawt M, et al. Allergy. 2023 Jan;78(1):71-83. doi: 10.1111/all.15571. Epub 2022 Nov 23. Allergy. 2023. PMID: 36321821 Free PMC article.
Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics.
Munblit D, Greenhawt M, Brough HA, Pushkareva A, Karimova D, Demidova A, Warner JO, Kalayci O, Sediva A, Untersmayr E, Rodriguez Del Rio P, Vazquez-Ortiz M, Arasi S, Alvaro-Lozano M, Tsabouri S, Galli E, Beken B, Eigenmann PA. Munblit D, et al. Pediatr Allergy Immunol. 2022 Oct;33(10):e13851. doi: 10.1111/pai.13851. Pediatr Allergy Immunol. 2022. PMID: 36282136 Free PMC article.

See all "Cited by" articles

References

1. Keating M.J., Holmes R., Lerner S., Ho D.H. L-asparaginase and PEG asparaginase—past, present, and future. Leuk Lymphoma. 1993;10(Suppl):153–157. - PubMed
1. Heo Y.A., Syed Y.Y., Keam S.J. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019;79:767–777. - PMC - PubMed
1. Burke M.J., Devidas M., Maloney K., Angiolillo A., Schore R., Dunsmore K., et al. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma. 2018;59:1624–1633. - PMC - PubMed
1. Liu Y., Smith C.A., Panetta J.C., Yang W., Thompson L.E., Counts J.P., et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37:2051–2061. - PMC - PubMed
1. Bruusgaard-Mouritsen M.A., Jensen B.M., Poulsen L.K., Duus Johansen J., Garvey L.H. Optimizing investigation of suspected allergy to polyethylene glycols. J Allergy Clin Immunol. 2022;149:169–176. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

R21 AI139021/AI/NIAID NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Keating M.J., Holmes R., Lerner S., Ho D.H. L-asparaginase and PEG asparaginase—past, present, and future. Leuk Lymphoma. 1993;10(Suppl):153–157. - PubMed

[2] Keating M.J., Holmes R., Lerner S., Ho D.H. L-asparaginase and PEG asparaginase—past, present, and future. Leuk Lymphoma. 1993;10(Suppl):153–157. - PubMed

[3] Heo Y.A., Syed Y.Y., Keam S.J. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019;79:767–777. - PMC - PubMed

[4] Heo Y.A., Syed Y.Y., Keam S.J. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019;79:767–777. - PMC - PubMed

[5] Burke M.J., Devidas M., Maloney K., Angiolillo A., Schore R., Dunsmore K., et al. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma. 2018;59:1624–1633. - PMC - PubMed

[6] Burke M.J., Devidas M., Maloney K., Angiolillo A., Schore R., Dunsmore K., et al. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma. 2018;59:1624–1633. - PMC - PubMed

[7] Liu Y., Smith C.A., Panetta J.C., Yang W., Thompson L.E., Counts J.P., et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37:2051–2061. - PMC - PubMed

[8] Liu Y., Smith C.A., Panetta J.C., Yang W., Thompson L.E., Counts J.P., et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37:2051–2061. - PMC - PubMed

[9] Bruusgaard-Mouritsen M.A., Jensen B.M., Poulsen L.K., Duus Johansen J., Garvey L.H. Optimizing investigation of suspected allergy to polyethylene glycols. J Allergy Clin Immunol. 2022;149:169–176. - PubMed

[10] Bruusgaard-Mouritsen M.A., Jensen B.M., Poulsen L.K., Duus Johansen J., Garvey L.H. Optimizing investigation of suspected allergy to polyethylene glycols. J Allergy Clin Immunol. 2022;149:169–176. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase

Affiliations

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical